#USA #New York #Class Action #Gross Law Firm #Skye Bioscience

Overview of the Class Action Lawsuit

On January 15, 2026, the Gross Law Firm announced the initiation of a class action lawsuit against Skye Bioscience, Inc. (NASDAQ: SKYE). This legal action primarily targets shareholders who acquired SKYE shares between the dates of November 4, 2024, and October 3, 2025. Under the proposed lawsuit, the firm seeks to appoint lead plaintiffs to represent these shareholders due to alleged deceptive practices by the company's management.

Allegations of Misleading Statements

The core allegations in the lawsuit assert that Skye Bioscience's management made materially false statements regarding its lead product candidate, nimacimab. The complaint claims that the company failed to disclose critical information regarding the product's effectiveness and overstated its clinical prospects. These miscommunications allegedly led to inflated stock values that ultimately resulted in substantial financial losses for investors upon the revelation of the true situation.

Specifically, the lawsuit contends:

• - Nimacimab's effectiveness was inaccurately represented, suggesting a level of efficacy that it did not meet.
• - The clinical and regulatory outlook for the product was grossly exaggerated, misleading investors into a false sense of security regarding their investments.
• - As a result of these misleading statements and omissions, shareholders were misled during the specified class period, incurring significant losses when the truth emerged.

Registering for Participation

Shareholders interested in participating in this class action must take action before the approaching deadline of January 16, 2026. The Gross Law Firm encourages all affected individuals to register as there is no cost or obligation to join the lawsuit. Participants will be given access to portfolio monitoring software, which will provide updates regarding the case's progress.

To register for the class action, shareholders can visit the following link: Class Action Registration.

The Role of the Gross Law Firm

The Gross Law Firm has built a strong reputation as a respected national class action law firm. Their mission emphasizes the protection of investors' rights, especially in cases involving fraudulent or deceptive practices. The firm's commitment to holding companies accountable for misconduct ensures that stakeholders have a voice when misrepresentations impact their financial well-being.

Furthermore, they aim to recover losses incurred by investors as a result of misleading corporate statements. Their focus on responsible business practices highlights the importance of transparency and ethical conduct in the corporate world.

Contact Information
For more inquiries regarding this class action or to seek further clarification, shareholders may contact the Gross Law Firm directly:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Conclusion

As the deadline for registering in this class action approaches, affected shareholders are encouraged to take prompt action to ensure their voices are heard and to seek possible recovery for their losses. The allegations against Skye Bioscience underline the critical nature of truthful corporate communication, reminding investors to remain vigilant in assessing the information presented by companies they choose to invest in.